Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
20 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||Independent Chairman of the Board|
|46||2015||Chief Executive Officer, Director|
|53||2016||Chief Financial Officer|
|55||2017||Chief Scientific Officer|
|51||2014||Vice President - Clinical Operations|
- BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000
- BRIEF-Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
- BRIEF-Biohaven receives agreement from FDA on initial pediatric study plan for rimegepant
- BRIEF-Biohaven Pharma qtrly loss per share $1.19
- BRIEF-Biohaven announces FDA clearance of IND application for sublingual BHV-0223